Creating Hope Reauthorization Act of 2024

Bill: 118-hr-7384
Sponsor: full_name: Rep. McCaul, Michael T. [R-TX-10]
Introduced: 2024-02-15
Policy area: Health
Subjects: Child health

Drug safety, medical device, and laboratory regulation

Prescription drugs
Latest action: action_date: 2024-02-16
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2024-02-15
action_desc: Introduced in House
text: <p><b>Creating Hope Reauthorization Act</b> <b>of 2024</b></p> <p>This bill extends until FY2029 a Food and Drug Administration program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)</p>

tv_txt: I 118th CONGRESS 2d Session H. R. 7384 IN THE HOUSE OF REPRESENTATIVES February 15, 2024 Mr. McCaul (for himself, Ms. Eshoo , Mr. Bilirakis , Ms. Barragán , Mrs. Trahan , and Mr. Burgess ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to extend the authority of the Secretary of Health and Human Services to issue priority review vouchers to encourage treatments for rare pediatric diseases.

1. Short title This Act may be cited as the Creating Hope Reauthorization Act of 2024 . 2. Extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases Section 529(b)(5) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360ff(b)(5) ) is amended— (1) by striking September 30, 2024 each place it appears and inserting September 30, 2028 ; and (2) in subparagraph (B), by striking September 30, 2026 and inserting September 30, 2030 .